Polyrizon develops highly differentiated biological gels, including a unique Biogel aimed at protecting against COVID-19, built on its Capture & Contain platform technology. The platform is intended to prevent allergen and virus intrusion through the upper airways and eye cavities. Polyrizon has an existing reseller and investment relationship with Medigus, which was granted an exclusive license to resell Polyrizon’s products once they receive FDA approval. The company is advancing toward an FDA submission, and a new investment is intended to support that effort. Financially, Medigus currently holds 19.9% of Polyrizon and has signed a non-binding term sheet for an additional investment that would increase Medigus’s stake. There are no operating metrics disclosed in the article.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2020